This week in drug discovery (28 August – 1 September)  

News round-up for 28 August – 1 September by DDW Digital Content Editor Diana Spencer.

This week’s headline news features a stem-cell derived Parkinson’s therapy, a monoclonal antibody for head and neck cancer, an estrogen receptor degrader for breast cancer, a mitochondrial activator for long Covid, and the world’s first AI-designed bispecific T cell engager – reflecting the breadth of innovative approaches to disease being employed by researchers across the globe.

The top stories:

Stem cell derived Parkinson’s therapy shows promise

A stem cell derived investigational therapy for treating Parkinson’s disease has shown promise in early clinical trials.

FDA fast-tracks monoclonal antibody for head and neck cancer

Fast Track designation from the Food and Drug Administration (FDA) will accelerate the path to US submission for Alentis Therapeutics’ investigational monoclonal antibody.

ER degrader for breast cancer receives UK Innovation Passport

Arvinas and Pfizer UK have been awarded a UK Innovation Passport for vepdegestrant (ARV-471), an investigational PROTAC ER (estrogen receptor) degrader.

Axcella granted US patent for long Covid fatigue treatment

The US Patent and Trademark Office (USPTO) has granted a patent for Axcella Therapeutics’ long Covid treatment candidate AXA1125.

Etcembly announces immunotherapy drug designed by AI

British techbio Etcembly is coming out of stealth mode, kickstarting the next generation of immunotherapies with a pipeline of T cell receptor (TCR) therapeutics designed using generative AI.

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free